30 October 2020 - If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and to meaningfully change the course of Alzheimer’s disease.

Biogen and Eisai today announced that the EMA has confirmed it has accepted for review, following a standard timetable, the marketing authorisation application for aducanumab, an investigational treatment for Alzheimer’s disease. 

Clinical data from patients with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease demonstrate that treatment with aducanumab resulted in the removal of amyloid beta and better clinical outcomes.

Read Biogen press release